Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of IBI354 versus investigator's choice chemotherapy in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer
CTR20250364Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IBI354 in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by InnoCare Pharma. Started Mar 2025; status: active.
02
Drugs
IBI354
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20250364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250364.